The Lean Mass Hyper-Responder (LMHR): Risks, Research, And Self-Check

Have you ever tried a ketogenic or low-carb diet and noticed that your cholesterol — especially your LDL — went way up? If so, you may belong to a group of scientists now calling them Lean Mass Hyper-Responders (LMHRs).

These are typically lean, metabolically healthy people whose blood tests reveal a striking pattern on a keto diet: very high LDL cholesterol, very high HDL cholesterol, and very low triglycerides.

It’s a profile that has puzzled doctors and researchers because, on one hand, high LDL has long been linked to heart disease, yet these individuals often look exceptionally healthy in other ways.

The big question is: Does this LDL rise put LMHRs at greater risk for heart disease, or is it a harmless byproduct of fat metabolism on keto?

Recent studies — including imaging trials that examine plaque directly inside arteries — are beginning to provide us with answers.

I. Studies That Defined LMHR & What They Found

The term Lean Mass Hyper-Responder (LMHR) was first described by Norwitz, Feldman, and colleagues in 2020. They observed a pattern in certain ketogenic dieters: despite being lean, insulin-sensitive, and otherwise metabolically healthy, these individuals developed very high LDL cholesterol (often above 190–200 mg/dL), very high HDL cholesterol (frequently above 80 mg/dL), and very low triglycerides (usually under 70 mg/dL).

This unique lipid profile led researchers to wonder: are LMHRs at extreme cardiovascular risk because of their high LDL, or do their otherwise favorable markers protect them?

Two major studies provide some answers:

1. The KETO Trial (Budoff et al., 2024)

Researchers studied 80 LMHR or near-LMHR individuals who had been on keto for an average of 4.7 years, with mean LDL levels of 272 mg/dL (some as high as 591 mg/dL!).
They were compared to 80 matched controls from the Miami Heart (MiHeart) cohort who had much lower LDL (~123 mg/dL).
Using coronary calcium scoring (CAC) and coronary CT angiography (CCTA), the researchers found:
- No significant difference in coronary plaque burden between the keto LMHR group and controls.
- No correlation between LDL levels and plaque within either group.
Conclusion: After nearly 5 years on keto with very high LDL, LMHRs did not show more plaque than people with far lower LDL.

2. The KETO-CTA Study (Soto-Mota, Norwitz, Feldman, Budoff, et al., 2025)

This was a prospective longitudinal study following 100 LMHRs for one year.
At baseline, participants had extremely high LDL and ApoB, but very little plaque (median CAC = 0).
After one year, modest plaque progression was seen.
Crucially, ApoB and LDL-C levels did not predict plaque growth. Instead, baseline plaque burden was the strongest predictor: those who already had some plaque were the ones who progressed.
Conclusion: In LMHRs, “plaque predicts plaque” — not ApoB or LDL — at least in the short term.

Takeaway so far:
These two studies — one cross-sectional (Budoff 2024) and one longitudinal (Soto-Mota 2025) — both suggest that in carefully selected, metabolically healthy LMHRs, extremely high LDL levels do not necessarily translate into higher plaque burden over several years.

II. Plaque Size, Imaging, and What These Studies Tell Us

Traditionally, doctors estimate heart disease risk by looking at cholesterol numbers. But cholesterol alone doesn’t tell the whole story — what truly matters is whether cholesterol particles are building up as plaque inside the arteries.

That’s why imaging studies like coronary artery calcium (CAC) scoring and coronary CT angiography (CCTA) are so important: they let us see plaque directly, not just infer it from blood work.

Findings from the KETO Trial (Budoff 2024)

Despite average LDL levels of 272 mg/dL for nearly five years, LMHRs had low plaque burden.
CAC scores were a median of 0 (meaning no detectable calcium), and CCTA plaque scores were similarly minimal.
Their plaque levels were not significantly different from those of matched controls with much lower LDL.
Notably, there was no correlation between LDL levels and plaque size in this study.

Findings from the KETO-CTA Study (Soto-Mota 2025)

Participants also had very high LDL and ApoB, but started with minimal plaque.
Over one year, plaque volume increased slightly, but the changes were modest and not correlated with LDL or ApoB levels.
Instead, the presence of plaque at baseline was the best predictor of whether it would progress.

Why This Matters

These studies suggest: In LMHRs, plaque imaging tells us more about risk than cholesterol numbers alone. While LDL and ApoB are sky-high, they don’t seem to predict plaque progression in this unique group. Instead, the critical factor is whether plaque is already present when the diet is started.

III. Weaknesses and Limitations of Existing Data

The studies on LMHRs are fascinating, but we need to be cautious about how far we extend their conclusions. Several important limitations stand out:

1. Population Selection

The KETO Trial (Budoff 2024) and KETO-CTA (Soto-Mota 2025) studied highly selected groups: lean, metabolically healthy, with low triglycerides and high HDL.
These findings may not apply to the broader keto community, particularly those who are overweight, insulin-resistant, or already dealing with metabolic syndrome.

2. Study Design Issues

KETO Trial: Followed individuals on a keto diet for an average of 4.7 years, but used a cross-sectional design — a “snapshot” comparison of LMHRs versus controls at one point in time. This is useful for spotting associations but cannot determine how plaque changes over time.
KETO-CTA: Prospective, but limited to one year of follow-up, which is short compared to the decades over which atherosclerosis develops.
Lack of a non-LMHR keto control group means we don’t know if plaque behavior is unique to LMHRs or general to keto dieters.

3. Limited Measurement of Lifestyle Factors

Physical activity and cardiorespiratory fitness were not rigorously quantified. Most reports relied on lifestyle questionnaires, which are prone to bias.
Diet adherence was self-reported, and macronutrient tracking wasn’t standardized across participants.

4. LDL Range Bias

Nearly all participants had extremely high LDL and ApoB, so there wasn’t much variation to test whether modest LDL elevations behave differently from very high ones.

5. Event Data Missing

These studies measured plaque burden, not hard cardiovascular outcomes like heart attacks, strokes, or cardiac death. That leaves uncertainty about whether findings translate to real-world risk.

⚠️ Takeaway:
The LMHR data so far provide intriguing insights, suggesting that plaque, not LDL, is the key predictor of risk in this group. But the limitations remind us that much larger, longer, and more diverse studies are needed before we can declare high LDL “safe” in LMHRs.

Lean Mass hyper responders or LMHRs are those who have high LDL but not more plaque

IV. The Missing Link: Could Physical Activity / Fitness Modify Risk?

One of the major unanswered questions in the Lean Mass Hyper-Responder (LMHR) story is whether physical activity and cardiorespiratory fitness are the true modulators of risk.

Why was the activity not captured well in the studies

In both the KETO Trial (Budoff, 2024) and KETO-CTA (Soto-Mota, 2025), participants reported being generally healthy and active; however, there were no rigorous measurements of fitness.
Key tools, such as VO₂max testing, accelerometry, or structured exercise logs, were not utilized.
This leaves open the possibility that differences in activity levels could explain why some LMHRs exhibit plaque progression, while others remain disease-free.

How exercise could protect LMHRs

Energy flux: Active individuals burn more fat, which may help process circulating LDL particles more efficiently.
Muscle as a lipid sink: Trained skeletal muscle has higher mitochondrial density and a greater capacity to oxidize fats, reducing the time lipoproteins spend in circulation.
Endothelial health: Exercise improves blood vessel function, lowers inflammation, and enhances HDL’s ability to remove cholesterol from arteries.
Plaque stability: Regular activity favors the formation of calcified, stable plaques instead of soft, rupture-prone ones.

The working hypothesis

Active LMHRs with high LDL levels might be at a lower risk because their metabolism clears lipids more quickly, and their vessels remain healthier.
Inactive LMHRs may face a higher risk, since their high LDL is not counterbalanced by the protective effects of exercise and fitness.

The research gap

To date, no study has differentiated LMHRs by fitness level or objectively measured their physical activity. A trial that tracks LDL, ApoB, plaque imaging, and VO₂max over years could reveal whether fitness is the key to explaining the LMHR paradox.

Exercise may be the missing link on LMHR

VI. What This Means for Keto Dieters

If you’ve tried a ketogenic or low-carb diet and your LDL skyrocketed, you may wonder if you’re at risk. The current science suggests that if you fit the LMHR profile, the picture may be more nuanced than “high LDL = high danger.”

1. Know if You’re an LMHR

Look at your blood work:
- LDL-C ≥190 mg/dL
- HDL ≥60 mg/dL
- Triglycerides ≤80 mg/dL
If this matches your labs on keto, you may fall into the LMHR category.

2. Plaque Matters More Than Cholesterol Alone

Imaging (CAC or CCTA) shows that baseline plaque predicts progression, not LDL or ApoB alone.
If you already have plaque, it may continue to grow regardless of LDL numbers. If you don’t, your risk may be much lower than your cholesterol suggests.

3. Don’t Ignore ApoB and ApoA1

While ApoB hasn’t predicted plaque progression in LMHRs so far, it remains a strong risk marker in the general population.
ApoB /ApoA1 ratio can provide additional context for your doctor when evaluating risk.

4. Physical Activity Is Your Best Ally

Exercise may be the missing protective factor for LMHRs.
Aim to build muscle, improve cardiorespiratory fitness, and stay consistently active.
These habits improve endothelial function, stabilize plaques, and may offset the risks of high LDL.

5. Work with Your Doctor

Consider CAC or CCTA imaging if your LDL level is very high.
Track your ApoB, ApoA1, and hs-CRP alongside traditional cholesterol markers.
Consider periodic reassessment rather than relying only on LDL-C.

✅ Bottom line:
If you’re lean, healthy, and see your LDL skyrocket on keto, you may be an LMHR. The evidence so far suggests your risk depends less on cholesterol alone and more on whether you already have plaque and how active and fit you are.

Until larger studies are conducted, the best path forward is vigilance (including imaging and laboratory tests) and an active lifestyle.

Don’t Get Sick!

💡 Support This Work

Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.

🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!

Follow me on Facebook, Gab, Twitter (formerly known as X), and Telegram.

References:

Budoff, M., Manubolu, V. S., Kinninger, A., Norwitz, N. G., Feldman, D., Wood, T. R., Fialkow, J., Cury, R., Feldman, T., & Nasir, K. (2024). Carbohydrate restriction-induced elevations in LDL-cholesterol and atherosclerosis: The KETO trial. JACC: Advances, 3(8), 101109. https://doi.org/10.1016/j.jacadv.2024.101109
Norwitz, N. G., Feldman, D., Soto-Mota, A., & Voruganti, V. S. (2020). The lean mass hyper-responder phenotype: Characterizing extreme hypercholesterolemia in ketogenic dieters. Current Developments in Nutrition, 4(Supplement_2), 1654. https://doi.org/10.1093/cdn/nzaa054_041
Soto-Mota, A., Norwitz, N. G., Manubolu, V. S., Kinninger, A., Wood, T. R., Earls, J., Feldman, D., & Budoff, M. (2025). Longitudinal data from the KETO-CTA study: Plaque predicts plaque, ApoB does not. JACC: Advances, 4(7), 101686. https://doi.org/10.1016/j.jacadv.2025.101686

As an Amazon Associate, I earn from qualifying purchases

Discover more from Don't Get Sick!

Subscribe to get the latest posts sent to your email.

The Lean Mass Hyper Responder (LMHR): What We Know, What We Don’t, And Are You One

Introduction